Opinion/decision on a Paediatric investigation plan (PIP): Tybost,cobicistat, decision type: , therapeutic area: , PIP number: P/0360/2022

Opinion/decision on a Paediatric investigation plan (PIP): Lenvima,Lenvatinib, decision type: , therapeutic area: , PIP number: P/0280/2022

Opinion/decision on a Paediatric investigation plan (PIP): Rxulti,brexpiprazole, decision type: , therapeutic area: , PIP number: P/0294/2022

Opinion/decision on a Paediatric investigation plan (PIP): Cometriq,cabozantinib, decision type: , therapeutic area: , PIP number: P/0357/2022

Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro,Obinutuzumab, decision type: , therapeutic area: , PIP number: P/0296/2022

Opinion/decision on a Paediatric investigation plan (PIP): Maralixibat chloride, decision type: , therapeutic area: , PIP number: P/0298/2022

Human medicines European public assessment report (EPAR): Beovu, brolucizumab, Wet Macular Degeneration, Date of authorisation: 13/02/2020, Revision: 10, Status: Authorised

Orphan designation: Pomalidomide, Treatment of multiple myeloma, 08/10/2009, Expired

Human medicines European public assessment report (EPAR): Tandemact, pioglitazone,glimepiride, Diabetes Mellitus, Type 2, Date of authorisation: 08/01/2007, Revision: 22, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Humanized monoclonal antibody of IgG1 subtype targeting NRP1, decision type: , therapeutic area: , PIP number: P/0283/2022